Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Gap Up – Still a Buy?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) shares gapped up prior to trading on Tuesday . The stock had previously closed at $0.32, but opened at $0.3355. Northwest Biotherapeutics shares last traded at $0.3270, with a volume of 2,897,317 shares trading hands.

Northwest Biotherapeutics Trading Down 9.7%

The company’s 50 day moving average price is $0.25 and its 200-day moving average price is $0.25. The company has a market capitalization of $403.77 million, a PE ratio of -0.01 and a beta of -0.86.

Northwest Biotherapeutics (OTCMKTS:NWBO) last announced its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($18.22) earnings per share for the quarter. The company had revenue of $0.20 million for the quarter.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.